152 related articles for article (PubMed ID: 18957169)
1. Design and synthesis of new symmetrical derivatives of dihydropyridine containing a pyridyl group on the 3, 5-positions and evaluation of their cytotoxic and multidrug resistance reversal activity.
Foroughinia F; Javidnia K; Amirghofran Z; Mehdipour A; Miri R
J Pharm Pharmacol; 2008 Nov; 60(11):1481-9. PubMed ID: 18957169
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities.
Mehdipour AR; Javidnia K; Hemmateenejad B; Amirghofran Z; Miri R
Chem Biol Drug Des; 2007 Oct; 70(4):337-46. PubMed ID: 17937779
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.
Miri R; Mehdipour A
Bioorg Med Chem; 2008 Sep; 16(18):8329-34. PubMed ID: 18701304
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
[TBL] [Abstract][Full Text] [Related]
6. Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines.
Engi H; Sakagami H; Kawase M; Parecha A; Manvar D; Kothari H; Adlakha P; Shah A; Motohashi N; Ocsovszki I; Molnár J
In Vivo; 2006; 20(5):637-43. PubMed ID: 17091771
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines.
Firuzi O; Javidnia K; Mansourabadi E; Saso L; Mehdipour AR; Miri R
Arch Pharm Res; 2013 Nov; 36(11):1392-402. PubMed ID: 23674129
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents.
Zou ZH; Lan XB; Qian H; Huang WL; Li YM
Bioorg Med Chem Lett; 2011 Oct; 21(19):5934-8. PubMed ID: 21843940
[TBL] [Abstract][Full Text] [Related]
9. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
Zhou XF; Zhang L; Tseng E; Scott-Ramsay E; Schentag JJ; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):321-8. PubMed ID: 15585608
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyridines and multidrug resistance: previous attempts, present state, and future trends.
Zarrin A; Mehdipour AR; Miri R
Chem Biol Drug Des; 2010 Nov; 76(5):369-81. PubMed ID: 20925689
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives.
Bisi A; Meli M; Gobbi S; Rampa A; Tolomeo M; Dusonchet L
Bioorg Med Chem; 2008 Jul; 16(13):6474-82. PubMed ID: 18522868
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyridines: evaluation of their current and future pharmacological applications.
Edraki N; Mehdipour AR; Khoshneviszadeh M; Miri R
Drug Discov Today; 2009 Nov; 14(21-22):1058-66. PubMed ID: 19729074
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of some taxoids as multidrug resistance modulator.
Hasegawa T; Bai J; Zhang S; Wang J; Matsubara J; Kawakami J; Tomida A; Tsuruo T; Hirose K; Sakai J; Kikuchi M; Abe M; Ando M
Bioorg Med Chem Lett; 2007 Feb; 17(4):1122-6. PubMed ID: 17239597
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
Kars MD; Işeri OD; Gunduz U; Molnar J
Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and multidrug resistance reversal activity of dihydroptychantol A and its novel derivatives.
Sun B; Yuan HQ; Xi GM; Ma YD; Lou HX
Bioorg Med Chem; 2009 Jul; 17(14):4981-9. PubMed ID: 19540127
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors.
Sirisha K; Shekhar MC; Umasankar K; Mahendar P; Sadanandam A; Achaiah G; Reddy VM
Bioorg Med Chem; 2011 May; 19(10):3249-54. PubMed ID: 21530277
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of cytotoxicity of novel chromeno[4,3-b]quinoline derivatives.
Miri R; Motamedi R; Rezaei MR; Firuzi O; Javidnia A; Shafiee A
Arch Pharm (Weinheim); 2011 Feb; 344(2):111-8. PubMed ID: 21290427
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells.
Hasegawa T; Bai J; Dai J; Bai L; Sakai J; Nishizawa S; Bai Y; Kikuchi M; Abe M; Yamori T; Tomida A; Tsuruo T; Hirose K; Ando M
Bioorg Med Chem Lett; 2007 Jul; 17(13):3722-8. PubMed ID: 17490878
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents.
Schmidt M; Teitge M; Castillo ME; Brandt T; Dobner B; Langner A
Arch Pharm (Weinheim); 2008 Oct; 341(10):624-38. PubMed ID: 18816589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
